Skip to main content

Our Expertise

Personalized Medicine partnerships rely on technologies in which bioMérieux has a long history of established expertise: 

  • Microbiology
  • Immunoassays
  • Molecular Biology
     

Companion tests

These mandatory diagnostic tests are used to select patients likely to show a clear benefit from an intervention (therapy, vaccine or device) for a given disease (patient stratification) and to identify patients with predispositions to serious side effects.

  • bioMérieux has acquired significant experience in this field, working with major pharmaceutical companies such as GSK, Novartis, Pfizer to develop THXID®-BRAF (a molecular-based Companion Diagnostic test to identify melanoma patients with BRAF V 600E/K mutations) as well as with other pharmaceutical partners to develop immunoassay-based CDx candidates. 
Companion tests


 

Supportive/Complementary tests

These diagnostic tests are recommended for safe drug or vaccine prescription or medical device use, and for good medical practice.

  • Tests used to optimize clinical trials through patient stratification and cohort enrichment.
    • Many of the tests on the BIOFIRE® (e.g. Respiratory panels) and VIDAS® systems (NEPHROCHECK® in the field of AKI), as well as certain microbiology growth-based assays (RAPIDEC® CARBA NPCHROMID®), can be used to efficiently select patients for treatment with prophylactic or therapeutic monoclonal antibodies, anti-infective medications or immuno-modulatory drugs as well as drugs involved in AKI.
  • Tests recommended for safe drug or vaccine utilization or effective medical device use, and for good medical practice.
    • In particular, tests used to determine antibiotic susceptibility (e.g. Minimum Inhibitory Concentration (MIC)) and to accompany their safe prescription.
    • For many years, bioMérieux has applied its partnership know-how in the field of infectious diseases to coordinate the development of the ETEST® and VITEK® 2 product ranges, in close collaboration with anti-infective pharmaceutical companies. Both these diagnostic solutions play an instrumental role in supporting the adoption and safe prescription of new anti-infective medications and avoiding their misuse, particularly in the context of growing antimicrobial resistance.

 

Supportive tests